 | Up a level |
Helbling, D.; Bodoky, G.; Gautschi, O.; Sun, H.; Bosman, F.; Gloor, Beat; Burkhard, R.; Winterhalder, R.; Madlung, Axel; Rauch, Daniel; Saletti, P.; Widmer, L.; Borner, M.; Baertschi, D.; Yan, P.; Benhattar, J.; Leibundgut, Elisabeth O.; Bougel, S.; Koeberle, D. (2013). Neoadjuvant chemoradiotherapy with or without panitumumab in patients with wild-type KRAS, locally advanced rectal cancer (LARC): a randomized, multicenter, phase II trial SAKK 41/07. Annals of oncology, 24(3), pp. 718-725. Oxford University Press 10.1093/annonc/mds519
Madlung, Axel; Simcock, Mathew; Ghadjar, Pirus (2011). Comparative risk-adjusted mortality outcomes after primary surgery, radiotherapy, or androgen-deprivation therapy for localized prostate cancer. Cancer, 117(15), 3532; author reply 3532-3. New York, N.Y.: John Wiley & Sons 10.1002/cncr.25456
Ghadjar, Pirus; Gwerder, Nicole; Manser, Peter; Vock, Jacqueline; Madlung, Axel; Mini, Roberto; Aebersold, Daniel M (2010). High-dose (80 Gy) intensity-modulated radiation therapy with daily image-guidance as primary treatment for localized prostate cancer. Strahlentherapie und Onkologie, 186(12), pp. 687-92. Heidelberg: Urban and Vogel 10.1007/s00066-010-2180-8
Ghadjar, Pirus; Gwerder, Nicole; Madlung, Axel; Behrensmeier, Frank; Thalmann, George N; Mini, Roberto; Aebersold, Daniel M (2009). Use of gold markers for setup in image-guided fractionated high-dose-rate brachytherapy as a monotherapy for prostate cancer. Strahlentherapie und Onkologie, 185(11), pp. 731-5. Heidelberg: Urban and Vogel 10.1007/s00066-009-2007-7
Ghadjar, Pirus; Vock, Jacqueline; Vetterli, Daniel; Manser, Peter; Bigler, Roland; Tille, Jan; Madlung, Axel; Behrensmeier, Frank; Mini, Roberto; Aebersold, Daniel M (2008). Acute and late toxicity in prostate cancer patients treated by dose escalated intensity modulated radiation therapy and organ tracking. Radiation oncology, 3, p. 35. London: BioMed Central 10.1186/1748-717X-3-35
